Literature DB >> 35999266

PSA screening in high-risk groups: what are the changes in benefits and harm?

Takeshi Takahashi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35999266      PMCID： PMC9519562          DOI： 10.1038/s41416-022-01947-8

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   9.075


× No keyword cloud information.
  5 in total

1.  Some experiences with latent carcinoma of the prostate.

Authors:  R S TOTTEN
Journal:  Bull N Y Acad Med       Date:  1953-07

Review 2.  A Urologist's Personal View of Prostate Cancer.

Authors:  Paul F Schellhammer
Journal:  Turk J Urol       Date:  2016-09

3.  Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88.

Authors:  Urs E Studer; Dieter Hauri; Silvia Hanselmann; Dominique Chollet; Hans-Jürg Leisinger; Thomas Gasser; Edgar Senn; Felix B Trinkler; Reto M Tscholl; George N Thalmann; Daniel Dietrich
Journal:  J Clin Oncol       Date:  2004-10-15       Impact factor: 44.544

4.  Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

Authors:  Laura J Esserman; Ian M Thompson; Brian Reid; Peter Nelson; David F Ransohoff; H Gilbert Welch; Shelley Hwang; Donald A Berry; Kenneth W Kinzler; William C Black; Mina Bissell; Howard Parnes; Sudhir Srivastava
Journal:  Lancet Oncol       Date:  2014-05       Impact factor: 41.316

Review 5.  Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.

Authors:  Jana McHugh; Edward J Saunders; Tokhir Dadaev; Eva McGrowder; Elizabeth Bancroft; Zsofia Kote-Jarai; Rosalind Eeles
Journal:  Br J Cancer       Date:  2021-12-18       Impact factor: 9.075
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.